Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate- risk non-muscle-invasive bladder cancer Accessibility Statement Skip Navigation- Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer- Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profileRARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & ...